Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.

Aflibercept plus anti-PDGFRβ combo does not improve vision outcomes in nAMD

16 Feb 2020
The bright spots in this human eye scan are signs of macular degeneration. Photo credit: National Eye Institute

The combination of intravitreal aflibercept and antiplatelet-derived growth factor receptor β (anti-PDGFRβ) falls short of improving best-corrected visual acuity (BCVA) in patients with treatment-naïve neovascular age-related macular degeneration (nAMD), as compared with intravitreal aflibercept injection (IAI) monotherapy, a phase II study has shown.

Anatomic outcomes evaluating complete fluid resolution also favour IAI.

This study randomized 505 patients with nAMD 1:2:2 to low-dose combination intravitreal anti-PDGFRβ 1 mg and aflibercept 2 mg (LD combo), high-dose combination intravitreal anti-PDGFRβ 3 mg and aflibercept 2 mg (HD combo), or IAI alone every 4 weeks through week 12.

Patients in the HD combo and IAI groups were then rerandomized at week 12 to continue as assigned or switch from HD combo to IAI or IAI to HD combo and dosed every 4 weeks through week 28. During weeks 28 to 52, patients received treatment as needed per prespecified criteria.

Mean BCVA gains at week 12 from baseline were 5.8 letters with LD combo, 5.8 with HD combo and 7.5 with IAI (LD combo: p=0.21; HD combo vs IAI: p=0.01). The corresponding proportions of eyes that gained ≥15 letters were 12 percent, 19 percent and 22 percent.

Mean reductions in central retinal thickness from baseline were 126.1 μm with LD combo, 127.1 μm with HD combo and 126.9 μm with IAI. The proportions of eyes with complete resolution of fluid from baseline were 35 percent, 24 percent and 42 percent, respectively.

At week 28, vision and anatomic outcomes were consistent with those from week 12. Through week 52, the corresponding incidence of intraocular inflammation was 1.0 percent, 7.5 percent, 2.1 percent, 2.1 percent and 0 percent. The incidence of Anti-Platelet Trialists’ Collaboration–defined arterial thromboembolic events was 1.9 percent, 0.9 percent, 1.1 percent, 2.1 percent and 1.9 percent, respectively.

“Adverse events were consistent with the reported IAI safety profile, except for a higher frequency of intraocular inflammation in the HD combo group,” the authors said.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Pearl Toh, 6 days ago
Every-two-month injections of the long-acting cabotegravir + rilpivirine were noninferior to once-monthly injections for virologic suppression at 48 weeks in people living with HIV*, according to the ATLAS-2M** study presented at CROI 2020 — thus providing a potential option with more convenient dosing.
Stephen Padilla, 19 Mar 2020
The assumption that children are less vulnerable to the coronavirus disease 2019 (COVID-19) compared to adults is not quite true and may even be dangerous, suggests a recent study.
22 Mar 2020
Sustained use of lopinavir-combined regimen appears to confer benefits among patients with the novel coronavirus disease (COVID-19), with improvement possibly indicated by increasing eosinophils, suggests a recent study.
24 Mar 2020
COVID-19 is a novel disease, with no existing immunity. The virus can be transmitted from person to person, quickly and exponentially. Here’s what we can do to slow down the spread, if not contain the outbreak.